Consensus: Guidelines for acromegaly management

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 9, 2002, Pages 4054-4058

  Melmed, S ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Casanueva, F F ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Cavagnini, F ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Chanson, P ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Frohman, L ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Grossman, A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Ho, K ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Kleinberg, D ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Lamberts, S ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Laws, E ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Lombardi, G ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Vance, M L ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Von Werder, K ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Wass, J ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Giustina, A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c UNIVERSITY OF MILAN   (Italy)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^g GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^h NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF VIRGINIA   (United States)

^k 1st School of Medicine   (Italy)

^l Schlosspark Klinik   (Germany)

^m RADCLIFFE INFIRMARY   (United Kingdom)

ⁿ UNIVERSITY OF BRESCIA   (Italy)

^o CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RECEPTOR ANTAGONIST; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ACROMEGALY; CONFERENCE PAPER; CRANIOTOMY; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; OUTCOMES RESEARCH; PRIORITY JOURNAL; STEREOTAXIC SURGERY; TRANSSPHENOIDAL SURGERY; CONSENSUS DEVELOPMENT; HYPOPITUITARISM; PRACTICE GUIDELINE;

ACROMEGALY; DOPAMINE AGONISTS; HUMANS; HYPOPITUITARISM;

EID: 18544363593     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-011841     Document Type: Conference Paper

References (39)

1. Melmed S 1990 Acromegaly. N Engl J Med 322:966-977
2. Melmed S, Jackson I, Kleinberg D, Klibanski A 1998 Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 83:2646-2652
3. Frohman LA 1996 Acromegaly: what constitutes optimal therapy? J Clin Endocrinol Metab 81:443-445
4. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
5. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB 1998 Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83:3411-3418
6. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 41:95-102
7. Bates AS, Van't Hoff W, Jones JM, Clayton RN 1993 An audit of outcome of treatment in acromegaly. Q J Med 86:293-299
8. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol Metab 85:526-529
9. Ross DA, Wilson CB 1988 Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg 68:854-867
10. Fahlbusch R, Honegger J, Buchfelder M 1992 Surgical management of acromegaly. Endocrinol Metab Clin North Am 21:669-692
11. Jenkins D, O'Brien I, Johnson A, Shakespear R, Sheppard MC, Stewart PM 1995 The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Clin Endocrinol (Oxf) 43:517-22
12. Davis DH, Laws Jr ER, Ilstrup DM, Speed JK, Caruso M, Shaw EG, Abboud CF, Scheithauer BW, Root LM, Schleck C 1993 Results of surgical treatment for growth hormone-secreting pituitary adenomas. J Neurosurg 79:70-75
13. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Cali A, de Divitiis E, Lombardi G 1997 Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308-3314
14. Freda PU, Wardlaw SL, Post KD 1998 Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 89:353-358
15. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S 1997 Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 100:2386-2392
16. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ 1996 Octreotide. N Engl J Med 334:246-254
17. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF 1995 Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study [published erratum appears in J Clin Endocrinology Metab 1995 Nov;80(11):3238]. J Clin Endocrinol Metab 80:2768-2775
18. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G, Giordano Disem G 1997 Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest 27:277-284
19. Chanson P 1997 Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits? Eur J Endocrinology 136:359-61
20. Jaffe CA, Barkan AL 1992 Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 21:713-735
21. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C, Jervell J 1997 Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab. 82:23-28
22. Caron P, Morange-Ramos I, Cogne M, Jaquet P 1997 Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab. 82:18-22
23. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A 1998 Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83:374-378
24. Gillis JC, Noble S, Goa KL 1997 Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 53:681-699
25. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
26. Herman-Bonert VS, Zib K, Scarlett JA, Melmed S 2000 Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab. 85:2958-2961
27. Eastman RC, Gorden P, Glatstein E, Roth J 1992 Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 21:693-712
28. Freda PU, Andreadis CI, Khandji AG, Khoury M, Bruce JN, Jacobs TP, Wardlaw SL 2000 Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab. 85:8-13
29. Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, Wellis G 1998 Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 88:1002-1008
30. Laws ER, Vance ML 1999 Radiosurgery for pituitary tumors and craniopharyngiomas. Neurosurg Clin N Am 10:327-336
31. Thalassinos NC, Tsagarakis S, Ioannides G, Tzavara I, Papavasiliou C 1998 Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in acromegaly: a long-term follow-up study. Eur J Endocrinol 138:160-163
32. Ciric I, Ragin A, Baumgartner C, Pierce D 1997 Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 40:225-37
33. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM, Wass JA 1996 Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 45:407-413
34. Brada M, Ford D, Ashley S, Bliss JM, Crowley S, Mason M, Rajan B, Traish D 1992 Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. Br Med J 304:1343-1346
35. Tsang RW, Laperriere NJ, Simpson WJ, Brierley J, Panzarella T, Smyth HS 1993 Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 72:2227-2233
36. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM 1997 Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82:3187-3191
37. Melmed S 1998 Tight control of growth hormone: an attainable outcome for acromegaly treatment. J Clin Endocrinol Metab 83:3409-3410
38. Consensus statement: benefits versus risks of medical therapy for acromegaly 1994 Acromegaly Therapy Consensus Development Panel. Am J Med 97:468-473
39. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL 1998 Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83:3034-3040